Cart
sales@molnova.com
JH-VIII-49
CAS No. 2209084-73-9
JH-VIII-49( —— )
Catalog No. M13522 CAS No. 2209084-73-9
JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameJH-VIII-49
-
NoteResearch use only, not for human use.
-
Brief DescriptionJH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
-
DescriptionJH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM); displays excellent selectivity against a panel of 468 kinases at a concentration of 10 uM, only 4 has >90% inhibition; induces a dose-dependent inhibition of S727-STAT1 phosphorylation in HepG2 cells (at 5 uM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2209084-73-9
-
Formula Weight428.664
-
Molecular FormulaC30H40N2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(3S,8S,10R,13S,14S,17S)-17-(isoquinolin-7-yl)-N,N,10,13-tetramethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. John M. Hatcher, et al. ACS Med. Chem. Lett. DOI: 10.1021/acsmedchemlett.8b00011
molnova catalog
related products
-
AZD 5597
A highly potent cyclin-dependent kinase (CDK) inhibitor with IC50 of 2 nM for both CDK1 and CDK2; exhibits anti-proliferative activity against LoVo cells with IC50 of 39 nM.
-
Cortistatin A
A potent and selective inhibitor of mediator-associated kinase CDK8 (IC50=12 nM) and its paralogue CDK19.
-
iCDK9
iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.
